ArticleCPT: pharmacometrics & systems pharmacology2021

Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer.

Phillip Spinosa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.